Clinical Efficacy and Patient Reported Impacts of Roflumilast Foam 0.3% in Seborrheic Dermatitis: An Analysis of STRATUM Data for Patients Unresponsive or Intolerant to Topical Corticosteroids. J of Skin [Internet]. 2024 Mar. 18 [cited 2025 Apr. 13];8(2):s397. Available from: https://skin.dermsquared.com/skin/article/view/2589